Target Name: MIR141
NCBI ID: G406933
Review Report on MIR141 Target / Biomarker Content of Review Report on MIR141 Target / Biomarker
MIR141
Other Name(s): MIRN141 | MicroRNA 141 | hsa-miR-141-3p | hsa-mir-141 | mir-141 | microRNA 141 | hsa-miR-141-5p

MIR141: A Potential Drug Target and Biomarker

MIR141 (MIM-141) is a protein that is expressed in various tissues of the body, including the brain, pancreas, and gastrointestinal tract. It is a member of the MIM (MutL homolog 1) gene family, which encodes for proteins that have has been implicated in various cellular processes, including DNA replication, cell signaling, and tissue repair. One of the unique features of MIR141 is its ability to interact with DNA-protein complexes, which may have implications for its function in gene regulation and cellular signaling.

In recent years, the study of MIR141 has gained significant interest due to its potential as a drug target and biomarker. Several studies have identified MIR141 as a potential drug target, with potential inhibitors being explored for its use in treating various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In addition, MIR141 has also been identified as a potential biomarker for several diseases, including pancreatic cancer and neurodegenerative diseases.

One of the potential advantages of MIR141 as a drug target is its involvement in various cellular signaling pathways. MIR141 has been shown to play a role in the regulation of DNA replication and repair, as well as in the regulation of cellular signaling pathways, including the T-cell receptor signaling pathway. MIR141 has also been shown to interact with various proteins that are involved in these signaling pathways, including T-cell receptor signaling pathway components such as PD-L1 and PD-L2.

In addition to its potential role in cellular signaling pathways, MIR141 has also been shown to be involved in the regulation of gene expression. Several studies have shown that MIR141 can interact with various transcription factors, including NF-kappa-B and AP-1, and can regulate their activity. This may have implications for the regulation of cellular processes that are important for human health, including the regulation of inflammation, cell signaling, and tissue repair.

As a potential biomarker, MIR141 has been shown to be involved in the regulation of several diseases, including pancreatic cancer and neurodegenerative diseases. In pancreatic cancer, MIR141 has been shown to be involved in the regulation of cell signaling pathways, including the T-cell receptor signaling pathway. MIR141 has also been shown to interact with PD-L1, a protein that has been shown to promote the development of cancer. By inhibiting PD-L1 function, MIR141 may have potential as a therapy for pancreatic cancer.

In neurodegenerative diseases, MIR141 has been shown to be involved in the regulation of cellular processes that are important for the maintenance of neural tissue homeostasis. MIR141 has been shown to interact with various proteins that are involved in these processes, including neurotrophins and tightly-packed chromatin domains. These interactions may have implications for the regulation of neural tissue homeostasis and the maintenance of brain health.

In conclusion, MIR141 is a protein that has potential as a drug target and biomarker. Its involvement in various cellular signaling pathways and its involvement in the regulation of gene expression make it an attractive target for drug development. Further research is needed to fully understand the function of MIR141 in these processes and to determine its potential as a therapy for various diseases.

Protein Name: MicroRNA 141

The "MIR141 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR141 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR142 | MIR143 | MIR144 | MIR145 | MIR1468 | MIR1469 | MIR146A | MIR146B | MIR1470 | MIR1471 | MIR147A | MIR147B | MIR148A | MIR148B | MIR149 | MIR150 | MIR151A | MIR151B | MIR152 | MIR153-1 | MIR153-2 | MIR1537 | MIR1538 | MIR1539 | MIR154 | MIR155 | MIR155HG | MIR1587 | MIR15A | MIR15B | MIR16-1 | MIR16-2 | MIR17 | MIR17HG | MIR181A1 | MIR181A1HG | MIR181A2 | MIR181A2HG | MIR181B1 | MIR181B2 | MIR181C | MIR181D | MIR182 | MIR1825 | MIR1827 | MIR183 | MIR184 | MIR185 | MIR186 | MIR187 | MIR188 | MIR18A | MIR18B | MIR1908 | MIR1909 | MIR190A | MIR190B | MIR191 | MIR1910 | MIR1911 | MIR1912 | MIR1913 | MIR1914 | MIR1915 | MIR1915HG | MIR192 | MIR193A | MIR193B | MIR193BHG | MIR194-1 | MIR194-2 | MIR194-2HG | MIR195 | MIR196A1 | MIR196A2 | MIR196B | MIR197 | MIR1972-1 | MIR1972-2 | MIR1973 | MIR1976 | MIR198 | MIR199A1 | MIR199A2 | MIR199B | MIR19A | MIR19B1 | MIR19B2 | MIR200A | MIR200B | MIR200C | MIR200CHG | MIR202 | MIR202HG | MIR203A | MIR203B | MIR204 | MIR205 | MIR2052 | MIR2052HG